Online citations, reference lists, and bibliographies.

Lenalidomide And CC-4047 Inhibit The Proliferation Of Malignant B Cells While Expanding Normal CD34+ Progenitor Cells.

Dominique Verhelle, Laura G. Corral, Kevin Wong, Jessica Müller, Laure A Moutouh-de Parseval, Kristen Jensen-Pergakes, Peter H. Schafer, Roger Chen, Emilia Glezer, Gregory D. Ferguson, Antonia Lopez-Girona, George W. Muller, Helen A Brady, Kyle W. H. Chan
Published 2007 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Clinical studies involving patients with myelodysplastic syndromes or multiple myeloma have shown the efficacy of lenalidomide by reducing and often eliminating malignant cells while restoring the bone marrow function. To better understand these clinical observations, we investigated and compared the effects of lenalidomide and a structurally related analogue, CC-4047, on the proliferation of two different human hematopoietic cell models: the Namalwa cancer cell line and normal CD34+ progenitor cells. Both compounds had antiproliferative effects on Namalwa cells and pro-proliferative effects on CD34+ cells, whereas p21WAF-1 expression was up-regulated in both cell types. In Namalwa cells, the up-regulation of p21WAF-1 correlated well with the inhibition of cyclin-dependent kinase (CDK) 2, CDK4, and CDK6 activity leading to pRb hypophosphorylation and cell cycle arrest, whereas in CD34+ progenitor cells the increase of p21WAF-1 did not inhibit proliferation. Similarly, antiproliferation results were observed in two B lymphoma cell lines (LP-1 and U266) but interestingly not in normal B cells where a protection of apoptosis was found. Finally, CC-4047 and lenalidomide had synergistic effects with valproic acid [a histone deacetylase (HDAC) inhibitor] by increasing the apoptosis of Namalwa cells and enhancing CD34+ cell expansion. Our results indicate that lenalidomide and CC-4047 have opposite effects in tumor cells versus normal cells and could explain, at least in part, the reduction of malignant cells and the restoration of bone marrow observed in patients undergoing lenalidomide treatment. Moreover, this study provides new insights on the cellular pathways affected by lenalidomide and CC-4047, proposes new potential clinical uses, such as bone marrow regeneration, and suggests that the combination of lenalidomide or CC-4047 with certain HDAC inhibitors may elevate the therapeutic index in the treatment of hematologic malignancies.
This paper references
10.1158/1078-0432.CCR-05-1437
Biological and Prognostic Significance of Chromosome 5q Deletions in Myeloid Malignancies
Aristoteles A N Giagounidis (2006)
10.1158/1535-7163.MCT-05-0448
Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells
Sudheer Kumar Mantena (2006)
10.1016/j.ejca.2006.04.004
Thalidomide and lenalidomide in the treatment of multiple myeloma.
Shaji K Kumar (2006)
10.1002/1097-0045(20010201)46:2<98::AID-PROS1013>3.0.CO;2-K
Detrimental effect of cancer preventive phytochemicals silymarin, genistein and epigallocatechin 3-gallate on epigenetic events in human prostate carcinoma DU145 cells.
Neehar Bhatia (2001)
The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma.
Martin F Kaiser (2006)
10.1016/j.leukres.2006.01.009
Novel valproic acid derivatives with potent differentiation-inducing activity in myeloid leukemia cells.
Hedwig E Deubzer (2006)
Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.
Laura G. Corral (1999)
10.1182/blood.V77.6.1218.bloodjournal7761218
Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells.
Leon W.W.M. Terstappen (1991)
10.1111/j.1365-2141.1994.tb06744.x
Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation.
William I. Bensinger (1994)
carcinoma DU 145 cells
Y Limdo (2001)
10.1182/blood.V96.9.2943
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Teru Hideshima (2000)
10.1016/j.hoc.2009.04.008
The myelodysplastic syndromes.
Phuong Nguyen (2009)
10.1158/0008-5472.CAN-04-3063
Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells.
Lidia De Felice (2005)
10.1038/nrc1323
The evolution of thalidomide and its IMiD derivatives as anticancer agents
J. Blake Bartlett (2004)
10.1158/1535-7163.MCT-05-0022
Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation
Marzia Pennati (2005)
10.1002/1097-0142(196901)23:1<64::AID-CNCR2820230107>3.0.CO;2-M
Characteristics of new cell lines derived from Burkitt lymphomas.
J. S. Nadkarni (1969)
10.1016/0092-8674(93)90499-G
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases
Jeffrey Harper (1993)
10.1182/blood.v91.12.4531.412k10_4531_4542
Regulation of p21(WAF1) expression during normal myeloid differentiation.
Richard Steinman (1998)
10.1158/0008-5472.CAN-04-3011
Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells.
Gesine Bug (2005)
10.1016/S0304-3835(01)00847-3
Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts.
Igor B. Roninson (2002)
10.1182/blood.v93.9.2907
Subcellular and cell-cycle expression profiles of CDK-inhibitors in normal differentiating myeloid cells.
Beatrice B. Yaroslavskiy (1999)
10.1038/nrc1780
KLF4, p21 and context-dependent opposing forces in cancer
Benjamin D. Rowland (2006)
10.1016/S0955-0674(02)00388-5
A revised picture of the E2F transcriptional network and RB function.
Olivier Stevaux (2002)
10.1080/14653240510027172
Ex vivo expansion of umbilical cord blood.
Simon N. Robinson (2005)
10.1158/1535-7163.MCT-05-0184
Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC
Xiao-Nan Li (2005)
10.1182/blood.V98.1.210
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Faith Davies (2001)
10.1053/j.seminhematol.2004.02.002
Myelodysplastic syndromes: From pathogenesis and prognosis to treatment.
Pierre Fenaux (2004)
10.1182/blood.V91.12.4531
Regulation of p21(WAF1) Expression During Normal Myeloid Differentiation
Richard A. Steinman (1998)
10.1016/s1040-1741(08)70122-2
Efficacy of Lenalidomide in Myelodysplastic Syndromes
Mark S. Gordon (2006)
10.1097/00001622-200111000-00010
Histone deacetylase inhibitors as new cancer drugs
Paul A. Marks (2001)
American Association for Cancer cancerres.aacrjournals.org Downloaded from
(2007)
10.1038/sj.bjc.6600607
Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects
Keith Dredge (2002)
10.1093/emboj/18.6.1571
The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts.
M Cheng (1999)
10.1101/gad.13.12.1501
CDK inhibitors: positive and negative regulators of G1-phase progression.
Charles J Sherr (1999)
10.1517/14712598.1.4.675
Immunotherapeutic and antitumour potential of thalidomide analogues
J Blake Marriott (2001)
10.1038/35060032
Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells
Binhua Peter Zhou (2001)
10.1016/S1535-6108(03)00165-X
Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?
Ricky W. Johnstone (2003)
10.1006/jmbi.1999.2640
Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors.
Nikola P. Pavletich (1999)
10.1182/blood.V88.10.3710.bloodjournal88103710
Involvement of p21cip-1 and p27kip-1 in the molecular mechanisms of steel factor-induced proliferative synergy in vitro and of p21cip-1 in the maintenance of stem/progenitor cells in vivo.
Charlie R. Mantel (1996)
10.1182/blood-2002-03-0996
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Paul G Richardson (2002)
10.1016/j.leukres.2006.01.010
Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly.
Anita K. Gandhi (2006)
Lenalidomide and CC-4047 Effects on Cells www.aacrjournals.org
RA Steinman (2007)
10.1038/sj.onc.1208474
Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities
Guangan He (2005)
10.1038/366701a0
p21 is a universal inhibitor of cyclin kinases
Yue Xiong (1993)
10.1016/S1368-7646(03)00044-X
Differential effects of cell cycle regulatory protein p21(WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy.
Suxing Liu (2003)
10.1016/S0304-419X(01)00019-1
Regulation of the retinoblastoma tumor suppressor protein by cyclin/cdks.
Peter Dow Adams (2001)
10.1002/jcp.20380
Inhibition of colon cancer cell proliferation by the dietary compound conjugated linoleic acid is mediated by the CDK inhibitor p21CIP1/WAF1.
Do Yoon Lim (2005)
American Association for Cancer cancerres.aacrjournals.org Downloaded from Lenalidomide and CC-4047 Effects on Cells www.aacrjournals.org 755
(2007)
10.1038/366704a0
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
M Rios Serrano (1993)



This paper is referenced by
10.1517/14712598.2013.799132
Perspectives in the treatment of multiple myeloma
Massimo Gentile (2013)
10.1080/10428190802365033
Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation
Owen A. O’Connor (2008)
10.1007/978-0-387-85816-6_11
Targeting Signal Transduction Pathways in Hematopoietic Disorders
Li Zhou (2009)
10.1007/s00277-012-1490-6
Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines
Maria Cosenza (2012)
10.1002/jcph.1145
In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects
Yan Li (2018)
10.1002/hon.2179
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.
Maria Cosenza (2015)
10.1160/TH08-01-0009
Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates.
Frank Gieseler (2008)
Risk of secondary primary malignancies in maintenance therapy for multiple
Herbert Irving Pavilion (2013)
10.1016/j.beha.2011.03.007
Translational development of vaccination strategies in follicular NHL.
Ippei Sakamaki (2011)
10.4161/onci.26494
Trial Watch
Michaela Semeraro (2013)
Chłoniak z komórek płaszcza - współczesne poglądy na diagnostykę i leczenie
Michal Szymczyk (2010)
10.1002/cncr.25377
Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma.
Greg Dueck (2010)
10.1073/pnas.0811267106
A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide
Sheng Cheng Wei (2009)
10.1038/onc.2012.599
Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy
Jake Shortt (2013)
10.1186/1756-8722-6-55
Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy
Madhav Desai (2013)
10.1002/ajh.21869
Prolonged 18FDG-PET negative complete remission in a heavily pretreated, elderly patient with diffuse large B cell lymphoma treated with lenalidomide, low dose dexamethasone, and colony stimulating factor (Rd-G).
Gerardo Musuraca (2011)
10.1111/j.1365-2141.2009.07626.x
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.
Thomas Matthew Habermann (2009)
10.1158/1078-0432.CCR-11-0212
Therapeutic Effect of Lenalidomide in a Novel Xenograft Mouse Model of Human Blastic NK Cell Lymphoma/Blastic Plasmacytoid Dendritic Cell Neoplasm
Alice Agliano (2011)
10.1111/j.1600-0609.2010.01542.x
Emerging therapies for the treatment of relapsed or refractory multiple myeloma.
Meletios Athanasios Dimopoulos (2011)
10.1074/jbc.M110.180208
Evidence of a Role for Activation of Wnt/β-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide
Chad C. Bjorklund (2010)
10.1517/14656566.2012.656091
Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies
Sonia Vallet (2012)
10.1007/s11864-011-0165-1
The 5q- Syndrome: Biology and Treatment
Eric Padron (2011)
10.4172/2167-0501.1000E116
Sickle Cell Disease: New Pharmacological Approaches
Jean Leandro dos Santos (2012)
10.1016/j.ctrv.2007.12.005
Lenalidomide: a new therapy for multiple myeloma.
Antonio Palumbo (2008)
10.1002/cpdd.470
An Open‐Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics
Yan Li (2019)
Improving the outcome of patients with lymphoproliferative disorders
Chan Yoon Cheah (2014)
10.1080/14656566.2018.1561865
Lenalidomide for the treatment of mantle cell lymphoma
Fortunato Morabito (2019)
10.1080/2162402X.2015.1115940
Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells
Pavel Otáhal (2016)
10.1186/1752-153X-6-125
Synthesis of hapten and preparation of specific polyclonal antibody with high affinity for lenalidomide, the potent drug for treatment of multiple myeloma
Ibrahim A Darwish (2012)
10.1586/ehm.11.2
Biology and treatment of the 5q- syndrome
Eric Padron (2011)
10.18632/oncotarget.5506
CD4+ T cells play a crucial role for lenalidomide in vivo anti-tumor activity in murine multiple myeloma
Liang Zhang (2015)
10.1254/FPJ.148.154
ポマリドミド(ポマリスト®カプセル1 mg/2 mg/3 mg/4 mg)の薬理学的/薬物動態学的特性および臨床試験成績
Kaoru Torigoe (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar